Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SMMT

Summit Therapeutics Inc

Apr 10 • 04:00PM ET

19.67

+0.36 1.86 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: XBI VTI VB VBR VXF IBB IWP IWF IWR SCHM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	86.17%	Shs Outstand	775.37M	Perf Week	1.50%
Market Cap	14.64B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	0.09%	Shs Float	102.98M	Perf Month	22.33%
Enterprise Value	13.95B	PEG	-	EPS next Q	-0.28	Inst Own	15.84%	Short Float	33.56%	Perf Quarter	4.46%
Income	-1.08B	P/S	-	EPS this Y	16.56%	Inst Trans	11.85%	Short Ratio	12.91	Perf Half Y	-15.72%
Sales	0.00M	P/B	23.15	EPS next Y	0.31%	ROA	-181.94%	Short Interest	34.56M	Perf YTD	12.46%
Book/sh	0.85	P/C	20.52	EPS next 5Y	39.70%	ROE	-206.10%	52W High	36.91 -46.71%	Perf Year	-2.38%
Cash/sh	0.96	P/FCF	-	EPS past 3/5Y	-52.45% -13.76%	ROIC	-159.62%	52W Low	13.83 42.23%	Perf 3Y	1185.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.90% 5.81%	Perf 5Y	249.38%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-369.70%	Oper. Margin	-	ATR (14)	1.00	Perf 10Y	181.40%
Dividend Ex-Date	-	Quick Ratio	9.87	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	65.84	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	9.87	EPS Q/Q	-244.58%	SMA20	13.10%	Beta	-1.39	Target Price	30.80
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	21.62%	Rel Volume	0.94	Prev Close	19.31
Employees	265	LT Debt/Eq	0.03	Earnings	Feb 23 AMC	SMA200	-0.68%	Avg Volume	2.68M	Price	19.67
IPO	Mar 05, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-274.68% -	Trades		Volume	2,520,830	Change	1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-26	Initiated	Stifel	Buy	$45
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$15
Dec-17-25	Upgrade	Barclays	Underweight → Equal Weight	$18
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Underweight	$13
Sep-04-25	Initiated	Guggenheim	Buy	$40
Aug-19-25	Initiated	Piper Sandler	Neutral	$21
Jul-01-25	Initiated	UBS	Buy	$30
Jun-11-25	Initiated	Leerink Partners	Underperform	$12
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7

Show Previous Ratings

Mar-27-26 08:15AM	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 (Business Wire)
Mar-03-26 02:21AM	Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment (Insider Monkey) -6.67%
Mar-02-26 02:56AM	Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab (Insider Monkey)
Feb-26-26 06:45PM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
09:38AM	RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View (Zacks)
08:02PM	Loading…
Feb-24-26 08:02PM	Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
11:31AM	SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus (Zacks)
08:30AM	Summit Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-23-26 08:17PM	Summit Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 (Business Wire)
Feb-22-26 07:47AM	Nvidia earnings, SCOTUS tariff fallout, geopolitical tensions rise: What to watch this week (Yahoo Finance)
Feb-17-26 05:05PM	Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 (Business Wire)
Feb-16-26 12:24PM	Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough (Insider Monkey)
Feb-13-26 10:49AM	MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell? (Zacks)
Feb-12-26 06:54AM	Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? (Insider Monkey)
08:00AM	Loading…
Feb-06-26 08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily) +8.23%
Feb-05-26 07:22AM	FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data (Insider Monkey)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-30-26 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.97%
10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
07:50AM	Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings (Zacks)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
07:30AM	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy (Business Wire)
05:20AM	Moderna holds a garage sale; Roche defends obesity drug data (BioPharma Dive)
Jan-28-26 06:57AM	Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive (Insider Monkey)
Jan-18-26 12:31PM	Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? (Benzinga)
Jan-15-26 10:20PM	Akeso Confident of Cancer Drug's FDA Approval Odds (Bloomberg)
Jan-12-26 12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga) -13.41%
12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
06:15AM	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) (Business Wire)
06:00AM	Loading…
06:00AM	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC (Business Wire)
Jan-09-26 08:16PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-26 07:30AM	Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.00%
Jan-02-26 09:10AM	Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst (Insider Monkey)
Dec-29-25 01:53PM	Top Research Reports for Apple, Cisco & IBM (Zacks)
Dec-17-25 09:59AM	Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? (Zacks)
Dec-11-25 07:44AM	Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development (Insider Monkey)
Dec-09-25 05:25PM	2 Stocks Up Over 600% in the Past 3 Years With More Room to Run (Motley Fool) -8.62% +5.41%
11:04AM	MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? (Zacks)
Dec-05-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:25PM	Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? (Motley Fool)
Dec-03-25 04:44AM	Don't Buy Summit Therapeutics Until This Big Thing Happen (Motley Fool) +6.49%
Dec-02-25 07:00AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Nov-27-25 09:45AM	AstraZeneca or Merck: Which Oncology Giant Has the Edge? (Zacks)
Nov-17-25 08:05AM	MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) -5.99%
Nov-10-25 08:19PM	Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial (Insider Monkey)
09:48AM	Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3? (Zacks)
Nov-07-25 09:00AM	Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China (Business Wire)
Nov-04-25 07:00AM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Oct-31-25 07:07AM	Insiders Are Snapping Up These 2 Stocks and Analysts Like What They See (TipRanks)
07:00AM	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 (Business Wire)
Oct-30-25 09:39PM	Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 (Insider Monkey)
Oct-28-25 06:43PM	Why Wall Street Is Backing These 3 Comeback Stocks (MarketBeat)
03:21PM	Insiders Are Buying These 3 Stocks Hand Over Fist (24/7 Wall St.)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
Oct-27-25 05:51AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-25-25 09:45AM	Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech (24/7 Wall St.)
Oct-24-25 07:00PM	Summit Therapeutics: A Risky Bet in the Biotech Arena? (Motley Fool)
04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks) -6.46%
09:24AM	Company News for Oct 21, 2025 (Zacks)
05:53AM	Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab (Insider Monkey)
Oct-20-25 03:00PM	Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com)
06:45AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 (Business Wire)
05:13AM	Summits dual-acting drug scores lung cancer win (BioPharma Dive)
Oct-19-25 10:30AM	Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China (Business Wire)
07:33AM	Tesla, Netflix set to report earnings as US-China trade fight turns 'unsustainable': What to watch this week (Yahoo Finance)
Oct-17-25 07:00AM	Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer (Business Wire)
Oct-15-25 07:00AM	Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 (Business Wire)
Oct-08-25 12:57AM	Where is Summit Therapeutics (SMMT) Headed According to Analysts? (Insider Monkey)
Oct-07-25 08:27AM	Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock? (Zacks)
Oct-05-25 09:45AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-02-25 01:35AM	H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones (Insider Monkey)
Oct-01-25 01:39PM	Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 (Insider Monkey)
Sep-24-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.05%
07:00AM	HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 (Business Wire)
Sep-22-25 10:21AM	Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds? (Zacks)
Sep-18-25 11:25PM	Jim Cramer on Summit Therapeutics: "We're Going to Have to Move On" (Insider Monkey) +6.30%
10:41AM	Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China (Insider Monkey)
Sep-12-25 07:57PM	Lightning Round: Ring the register on Opendoor, don't be in a meme stock, says Jim Cramer (CNBC TV)
Sep-11-25 10:05AM	Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock? (Zacks) +5.65%
Sep-10-25 12:59AM	Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating (Insider Monkey) -6.48%
Sep-09-25 01:17PM	SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study (Zacks)
05:58AM	S&P Futures Tick Higher Ahead of U.S. Payrolls Revisions (Barchart)
05:51AM	Is Summit Therapeutics a Buy, Sell, or Hold Now? (Motley Fool)
Sep-08-25 06:12PM	Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health (TheStreet) -25.15%
04:08PM	Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch (Investor's Business Daily)
11:26AM	Stock Market Today: Stocks rise as investors embrace supersized cut chances (TheStreet)
09:33AM	Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics (Yahoo Finance Video)
08:28AM	Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences (Benzinga)
07:53AM	New Summit data clouds approval pathway in lung cancer (BioPharma Dive)
Sep-07-25 03:30AM	Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC (Business Wire)
Sep-05-25 09:35AM	Apple upgraded, AMD downgraded: Wall Streets top analyst calls (TipRanks) +9.16%
Sep-04-25 09:33AM	Apple upgraded, AMD downgraded: Wall Street's top analyst calls (The Fly)
Sep-03-25 07:00AM	Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 (Business Wire)
Aug-31-25 06:45AM	3 No-Brainer Stocks to Buy Right Now (Motley Fool)
12:10AM	H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44 (Insider Monkey)
Aug-27-25 08:07AM	Stock Market Today: Stocks rise ahead of Nvidia's after hour earnings (TheStreet) -8.06%
Aug-19-25 09:06AM	Can Keytruda Sustain Merck's Growth Through the Rest of 2025? (Zacks)
Aug-18-25 11:43PM	Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism (Insider Monkey)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xia Yu	Director	Oct 21 '25	Buy	18.74	533,617	9,999,983	32,057,147	Oct 23 09:06 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:08 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:06 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:36 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:36 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:32 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:32 PM
Zanganeh Mahkam	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 05:01 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SMMT

Summit Therapeutics Inc

Upgrade your Finviz experience